Novel anti-obesity pharmacotherapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual receptor agonist of the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, have emerged as promising therapeutic options, demonstrating significant efficacy in promoting sustained weight reduction.16 Here, GIP is linked to obesity disorder.